Abingdon Health plc

("Abingdon Health" or "the Company")

Salistick™, the first ever saliva pregnancy test, to be launched in Tesco

York, U.K. 15 August 2023: Abingdon Health plc (AIM: ABDX), is pleased to announce that Tesco will roll-out Salistick™, the first-ever saliva pregnancy test, in 298 stores and online at Tesco.com from late-August 2023.

The launch of Salistick™ will be focused on larger Tesco stores as well as online at Tesco.com. This follows the initial launch of Salistick™ with Superdrug in 400 stores and online at Superdrug.com.

The Salistick™ pregnancy test offers women an improved user experience, with high accuracy for early pregnancy detection. The revolutionary patented technology allows saliva to be used as a sample rather than the traditional urine sample. Salistick™ offers the ability to test anywhere, anytime, and for the testing experience to be shared with a partner and other loved ones. It is estimated that 12.5 million pregnancy tests were performed in the UK in 2022. The global pregnancy test kits market was valued at USD 1.70 billion in 2022 and is expected to reach USD 2.28 billion by 2028, growing at a CAGR of 5.08%⁽¹⁾.

Abingdon Health is the exclusive distributor of Salistick™ in the UK and Ireland on behalf of Salignostics Limited, an Israeli developer of innovative saliva-based diagnostics tests. As well as providing distribution support Abingdon Health has been providing Salignostics with contract development services to scale-up the Salistick™ product for manufacture and will continue to provide Salignostics with contract manufacturing services going forward.

Chris Yates, CEO of Abingdon Health plc, commented: "We are delighted to announce the launch of Salistick™ with Tesco, online and rolled-out across nearly 300 larger Tesco stores. This novel technology provides women with an enhanced user-experience; offering the ability to test anywhere, anytime, and for the testing experience to be shared with a partner and other loved ones. We continue to explore distribution opportunities for Salistick™ both in the UK and internationally and we look forward to launching the Salistick™ dual pack in due course."

Sources:

1.     Pregnancy Test Kits Market Size, Share, Trends, Growth Forecast (arizton.com)

Enquiries

About Abingdon Health plc

Abingdon Health is a leading lateral flow contract development and manufacturing organisation ("CDMO") offering its services to an international customer base across industry sectors that include clinical, animal health, plant health, and environmental testing. Abingdon Health has the internal capabilities to take projects from initial concept through to routine and large-scale manufacturing; from "idea to commercial success."

The Company's CDMO division offers product development, regulatory support, technology transfer and manufacturing services for customers looking to develop new assays or transfer existing laboratory-based assays to a lateral flow format.  Abingdon Health aims to support the increase in need for rapid results across many industries and locations and produces lateral flow tests in areas such as infectious disease, clinical testing including companion diagnostics, animal health and environmental testing. Faster access to results allows for rapid decision making, targeted intervention and can support better outcomes. 

Abingdon Health's Abingdon Simply Test range of self-tests is an ecommerce platform that offers a range of self-tests to empowers consumers to manage their own health and wellbeing. The Abingdon Simply Test ecommerce site offers consumers a range of information to support them in making informed decisions on the tests available. In addition, the site provides Abingdon's contract services customers with a potential route to market for self-tests. The Abingdon Simply Test range is also sold through international distributors and through other channels in the UK and Ireland such as pharmacy chains.

Founded in 2008, Abingdon Health is headquartered in York, England.

For more information visit: www.abingdonhealth.com

This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.